PubMed:28807912
Annnotations
{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/28807912","sourcedb":"PubMed","sourceid":"28807912","text":"Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Challenge Model: A Phase 2 Randomized Trial.\nBACKGROUND: MHAA4549A, a human monoclonal antibody targeting the hemagglutinin stalk region of influenza A virus (IAV), is being developed as a therapeutic for patients hospitalized with severe IAV infection. Safety and efficacy of MHAA4549A were assessed in a randomized, double-blind, placebo-controlled, dose-ranging study in a human IAV-challenge model.\nMETHODS: One hundred healthy volunteers were inoculated with A/Wisconsin/67/2005 (H3N2) IAV and, 24-36 hours later, administered a single intravenous dose of either placebo, MHAA4549A (400, 1200, or 3600 mg) or a standard oral dose of oseltamivir. Subjects were assessed for safety, pharmacokinetics (PK), and immunogenicity. The intent-to-treat-infected (ITTI) population was assessed for changes in viral load, influenza symptoms, and inflammatory biomarkers.\nRESULTS: MHAA4549A was well tolerated in all IAV-challenge subjects. 3600-mg MHAA4549A significantly reduced viral burden relative to placebo as determined by the area under the curve (AUC) of nasopharyngeal virus infection, quantified using quantitative PCR (98%) and 50% tissue culture infective dose (TCID50) assays (100%). Peak viral load, duration of viral shedding, influenza symptoms scores, mucus weight, and inflammatory biomarkers were also reduced. Serum PK was linear with a half-life of ∼23 days. No MHAA4549A-treated subjects developed anti-drug antibodies.\nCONCLUSIONS: MHAA4549A was well tolerated, and demonstrated statistically significant and substantial antiviral activity in an IAV-challenge model.\nREGISTRY: ClinicalTrials.gov, NCT01980966.","tracks":[{"project":"IAV-Glycan_IAV_human_2","denotations":[{"id":"T1","span":{"begin":586,"end":590},"obj":"H3N2"}],"attributes":[{"subj":"T1","pred":"source","obj":"IAV-Glycan_IAV_human_2"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"IAV-Glycan_IAV_human_2","color":"#ad93ec","default":true}]}]}}